Hello guest, Register  |  Sign In
Virologica Sinica, 32 (5) : 0, 2017
Review (advanced Online Publication)
Recent progress on chikungunya virus research
1. Viral Disease and Vaccine Translational Research Unit, CAS Key Laboratory of Molecular Virology and
Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200025, China
2. Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College,
Pennsylvania 16802, United States
3. College of Pharmaceutical Sciences, Jilin University, Changchun 130021, China
 Correspondence: xjin@ips.ac.cn
(992.87KB)  
Abstract
Chikungunya virus (CHIKV) is an arbovirus transmitted by Aedes mosquitos in tropical and subtropical regions across the world. After decades of sporadic outbreaks, it re-emerged in Africa, Asia, India Ocean and America suddenly, causing major regional epidemics recently and becoming a notable global health problem. Infection by CHIKV results in a spectrum of clinical diseases including an acute self-limiting febrile illness in most individuals, a chronic phase of recurrent join pain in a proportion of patients, and long-term arthralgia for months to years for the unfortunate few. No specific anti-viral drugs or licensed vaccines for CHIKV are available so far. A better understanding of virus-host interactions is essential for the development of therapeutics and vaccines. To this end, we reviewed the existing knowledge on CHIKV’s epidemiology, clinical presentation, molecular virology, diagnostic approaches, host immune response, vaccine development, and available animal models. Such a comprehensive overview, we believe, will shed lights on the promises and challenges in CHIKV vaccine development.
Received: 23 Aug 2017  Accepted: 11 Nov 2017  Published online: 28 Nov 2017
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved